Community SpotlightPublicationsResearch NewsResearch Spotlight Down syndrome collaborators now published in Alzheimer’s and Dementia “Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome” published in the journal…Kate O’NeillMarch 15, 2024
Research NewsCommunity SpotlightResearch Spotlight LuMind IDSC statement on FDA Advisory Committee for promising Alzheimer’s drug, donanemab LuMind IDSC is encouraged by today’s news that the U.S. Food and Drug Administration (FDA)…Kate O’NeillMarch 8, 2024
Research NewsResearch Spotlight Study: Medicare, Medicaid, and Dual Enrollment for Adults with Intellectual and Developmental Disabilities. Medicare, Medicaid and Dual Enrollment for Adults with IDD Boston University School of Public Health…Shannon BergstresserJanuary 31, 2024
Community SpotlightResearch Spotlight Message from the CEO: a look ahead to 2024 “I want to enjoy my life for a long time. I want to grow old…Kate O’NeillJanuary 18, 2024
Community SpotlightResearch NewsResearch Spotlight Boston Globe OpEd People with Down Syndrome Now Left Out of Treatment LuMind IDSC and The Arc of Northeast collaborated on an OpEd that was recently published…Kate O’NeillSeptember 18, 2023
Research NewsResearch Spotlight Study: Use of Medicaid by Adults with Down Syndrome Medicaid Enrollment and Service Use Among Adults with Down Syndrome September 16, 2023 In a…Shannon BergstresserSeptember 16, 2023
Research NewsResearch Spotlight LuMind IDSC statement on FDA approval of Leqembi LuMind IDSC issues statement following FDA full approval of Leqembi™ to treat early-stage Alzheimer’s disease …Kate O’NeillJuly 7, 2023
Research NewsPress ReleaseResearch Spotlight Expert panel addresses inequitable access to Alzheimer’s drugs for adults with Down syndrome Seeking to rectify existing federal and state policies which prevent people with intellectual disabilities from…Kate O’NeillJune 1, 2023
Research NewsResearch Spotlight LuMind IDSC Statement re: Donanemab Phase 3 Results Pharmaceutical company Eli Lilly today announced results of a phase III clinical trial that proves…Kate O’NeillMay 3, 2023
Research SpotlightResearch NewsSleep Apnea Important progress in the treatment of sleep apnea and Down syndrome At the end of March, the US Food & Drug Administration approved Inspire’s Hypoglossal Nerve…Kate O’NeillMarch 29, 2023